Joflupan (123i) Rotop (Ioflupane (123i))

• Joflupan (123i) Rotop, containing ioflupane, is used in nuclear medicine to evaluate dopaminergic pathways in movement‑disorder diagnostics.
• Parkinsonian syndromes: enables visualization of striatal dopamine transporter loss, supporting diagnosis and disease staging in patients with suspected Parkinson’s disease.
• Differential diagnosis of movement disorders: helps distinguish Parkinsonian from non‑Parkinsonian conditions by assessing presynaptic dopaminergic integrity.
• Dementia with Lewy bodies: assists in identifying dopaminergic deficits characteristic of Lewy body dementia, aiding clinical differentiation from Alzheimer’s disease.
• Research applications: provides quantitative data for clinical trials evaluating neuroprotective therapies targeting dopaminergic neurons.

• Ioflupane is a radiolabeled analogue of the dopamine transporter ligand that, after intravenous injection, crosses the blood‑brain barrier and binds with high affinity to presynaptic dopamine transporters located in the striatum. The attached technetium‑99m gamma‑emitting isotope enables single‑photon emission computed tomography (SPECT) to generate images reflecting the density and functional integrity of dopaminergic neurons, thereby allowing clinicians to assess neurodegenerative changes.

Adverse reactions to Joflupan (123i) Rotop are generally related to the radiopharmaceutical nature of the preparation and the injection procedure.

Common Side Effects

• Injection site pain: mild discomfort or burning at the IV site, usually resolves quickly.
• Nausea: brief queasiness occurring shortly after administration, typically self‑limiting.
• Headache: mild to moderate headache during the imaging period, often relieved with simple analgesics.
• Dizziness: temporary light‑headedness after injection, generally brief.

Serious or Rare Side Effects

• Allergic reaction: urticaria, facial swelling, bronchospasm, or anaphylaxis requiring immediate treatment.
• Severe hypotension: sudden blood pressure drop causing fainting or cardiovascular instability.
• Radiation‑induced tissue injury: rare localized skin erythema or tissue damage at the injection site.

When using Joflupan (123i) Rotop, several precautions should be observed to ensure patient safety and product integrity.

• Patient screening: verify indication and assess for contraindications such as severe allergy to radiopharmaceuticals.
• Renal function: evaluate kidney function as impaired clearance may affect radiotracer distribution.
• Medication review: discontinue interfering drugs (e.g., dopamine‑reuptake inhibitors) that may alter tracer binding, if clinically appropriate.
• Radiation safety: follow institutional radiation protection protocols for handling and disposal of radioactive waste.
• Monitoring: observe patients for immediate adverse reactions during and after injection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Ioflupane may interact with certain medications or substances that influence dopamine transporter activity or radiopharmaceutical handling.

Major Interactions (Avoid)

• Dopamine reuptake inhibitors: drugs such as cocaine, methylphenidate, or certain antidepressants can competitively inhibit tracer binding, leading to inaccurate imaging results.
• Radiopharmaceuticals with overlapping emissions: concurrent administration of other nuclear agents may cause image interference.

Moderate Interactions (Monitor Closely)

• Antipsychotics: typical or atypical agents affecting dopamine pathways may alter tracer uptake and should be reviewed before imaging.
• Thyroid medications: excess iodide can affect technetium‑99m labeling efficiency, requiring monitoring of thyroid status.
• Herbal supplements: substances like St. John’s wort may modulate neurotransmitter systems and should be disclosed.